How is Trogarzo used in the treatment of HIV?
Medically reviewed by Drugs.com. Last updated on Oct 8, 2019.
Trogarzo (ibalizumab-uiyk) is used to treat the small percentage of patients who have multidrug-resistant human immunodeficiency virus type 1 HIV (MDR HIV-1 Infection) and who have failed other HIV therapies.
Trogarzo is a first-in-class CD4-directed post-attachment HIV-1 inhibitor that works by binding to CD4+ receptors on host cells and blocking the HIV virus from infecting the cells. It is the first monoclonal antibody approved for the treatment of MDR HIV-1 infection, and is used in combination with other antiretroviral drugs.
Trogarzo is administered intravenously (IV) once every 14 days by a trained medical professional.
Related Medical Questions
- How well does Trogarzo work to treat multidrug-resistant (MDR) HIV-1?
- What are the side effects with HIV treatment Trogarzo?
- Modafinil vs Adderall: What's the difference?
- Which medicines should not be taken with Biktarvy?
- Can Leronlimab (PRO 140) be used to treat COVID-19 (coronavirus)?
- Truvada vs Descovy: How do they compare for HIV and PrEP?
- What if I miss a dose of Biktarvy?